AlphAIAlphAI — Financial news for AI agents
prnewswire.com$VNDA

Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026

Vanda Pharmaceuticals (VNDA) will release its Q3 2026 financial results on October 28, 2026, after market close. A conference call will follow, with details provided for participation and replay. Vanda is a biopharmaceutical company focused on innovative therapies.

Original reporting
prnewswire.com
Published Oct 21, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 9:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026 — source image
Source · prnewswire.com
Decision brief

The 30-second read

$VNDANeutralLow
01

Why it matters

The announcement provides a concrete date for traders to schedule pre‑earnings positioning. No financial metrics are disclosed, so immediate trading decisions are limited.

02

Market read

Primary relevance is to Vanda shareholders and biotech traders; broader market impact is minimal until results are released.

03

What to watch

Potential regulatory updates or trial data releases could coincide with the earnings call, amplifying impact.

Relevance 5/10Novelty 5/10Timing: pre‑market on Oct 28 2026

Background

Vanda Pharmaceuticals is a Nasdaq‑listed biotech firm. The press release merely informs investors of the upcoming Q3 2026 earnings release date and conference call details.

Company-level read

Ticker impact

$VNDANeutralMedium confidence
Context

Vanda Pharmaceuticals announced the date and time for its Q3 2026 earnings release and conference call.

Expected impact

possible volatility as traders position ahead of the results; direction unclear until numbers are released

Evidence & confidence

Earnings dates typically generate pre‑release positioning, but no guidance or results are disclosed yet.

Market effects

Sector

Sets a timeline for the biotech/pharma sector's earnings calendar, but no sector‑wide impact yet.

Regional

U.S. market participants will note the timing for the Nasdaq‑listed stock.

Global

Limited to investors tracking Vanda and comparable biotech peers.

Counterpoint

What could challenge this read

If the market has already priced in strong results, the announcement could trigger a sell‑off on disappointment.

Key entities

  • company
    Vanda Pharmaceuticals Inc.

    Biopharmaceutical company announcing its Q3 2026 earnings release.

Read at source← All news

Related articles

$VNDAMed

H.C. Wainwright reiterates Buy on Vanda stock, cites sales growth

H.C. Wainwright reiterated a Buy rating and $20.00 price target on Vanda Pharmaceuticals (VNDA) after its Q3 2026 results. VNDA reported $69.8M in net sales and a $22.6M net loss, with full-year revenue expected to exceed $240M. Fanapt prescriptions rose 25% YoY and 72% QoQ. Bysanti received FDA approval and Nereus showed growth in prescriptions. VNDA beat earnings estimates, with shares up in after-hours trading.

investing.com
$VNDAMed

Vanda Pharmaceuticals Inc (VNDA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24%

Vanda Pharmaceuticals reported a 24% revenue increase in Q3 2026, but net loss widened to $133.6M for the first nine months. Hetlios sales declined 21% due to generic competition, and Nereus revenue is expected to be less than $10M for 2026. Cash reserves decreased by $123.4M. The company anticipates FDA decisions on Quimilza and Bisanti in 2027. CEO Mihael Polymeropoulos discussed commercial plans and clinical trial updates during the earnings call.

finance.yahoo.com
$VNDAMed

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Vanda Pharmaceuticals reported positive phase 3 trial results for tradipitant in preventing GLP-1-induced vomiting, planning an FDA sNDA submission. Eli Lilly's retatrutide outperformed Ozempic in a type 2 diabetes trial. Agios Pharmaceuticals' mitapivat FDA review extended to February 2027. FDA approved Voceryq for recurrent respiratory papillomatosis.

hcplive.com
$VNDAMed

Vanda (VNDA) Q3 2026 Earnings Call Transcript

Vanda Pharmaceuticals (VNDA) reported Q3 2026 earnings, with revenue up 24% YoY to $172.1M for the first nine months, driven by Fanapt's growth and NEREUS launch. Operating expenses decreased 18% QoQ. Key drugs like BYSANTI, Quimilza, and HETLIOZ are in various stages of FDA review and clinical trials. Fanapt saw a 25% increase in prescriptions, while HETLIOZ faced generic competition.

finance.yahoo.com
$VNDAMed

Vanda Pharmaceuticals Q3 Earnings Call Highlights

Vanda Pharmaceuticals reported Q3 sales of $7.7M for PONVORY, up 10% YoY, and $1.6M for NEREUS, up 60% QoQ. The company expects to launch BYSANTI in Q4 2026 and anticipates $240M+ in full-year 2026 revenue. Operating expenses decreased sequentially to $93.3M, while cash balance fell to $140.5M. Vanda plans FDA discussions for NEREUS and HETLIOZ applications.

finance.yahoo.com